Personal information

Other IDs

Scopus Author ID: 7101835155

Keywords

antibody, antigen, phage display, protein purification, immunotherapy, ADC, BiTE

Countries

Spain, United Kingdom

Activities

Collapse all

Employment (3)

University College London: London, London, GB

2018-10-01 to present | Senior Research Fellow (Research Department of Oncology)
Employment
Source: Self-asserted source
Enrique Miranda Rota

University College London: London, London, GB

2009-10-02 to 2018-09-30 | Research fellow (Cancer Institute)
Employment
Source: Self-asserted source
Enrique Miranda Rota

Abbott Laboratories Ltd: Queenborough, GB

2005-02-01 to 2005-09-15 | microbiologist (QC)
Employment
Source: Self-asserted source
Enrique Miranda Rota

Education and qualifications (4)

Barts and The London School of Medicine and Dentistry: London, London, GB

2005-10-01 to 2009-09-02 | PhD (Oncology)
Qualification
Source: Self-asserted source
Enrique Miranda Rota

Chartered Institute of Linguists: London, GB

2008 to 2008 | Diploma in Translation English-Spanish
Qualification
Source: Self-asserted source
Enrique Miranda Rota

Universidad de Navarra: Pamplona, Navarra, ES

2001-10-01 to 2004-06-01 | BSc Biochemistry
Qualification
Source: Self-asserted source
Enrique Miranda Rota

Universidad de Navarra: Pamplona, Navarra, ES

1999-09-01 to 2003-06-28 | BSc Biology
Qualification
Source: Self-asserted source
Enrique Miranda Rota

Professional activities (2)

The Antibody Society: Framingham, MA, US

Membership
Source: Self-asserted source
Enrique Miranda Rota

University College London: London, London, GB

2019-03-01 to present | Manager of non-mass spec Proteomics Platform (Cancer Institute)
Service
Source: Self-asserted source
Enrique Miranda Rota

Funding (3)

Antibody Treatments for Cervical Cancer

2016-07 to 2020-08 | Grant
Cancer Research Institute Trust (London, GB)
Source: Self-asserted source
Enrique Miranda Rota

Antibody Treatments for Cervical Cancer

2015-05 to 2020-08 | Grant
Cancer Institute Research Trust (London, US)
Source: Self-asserted source
Enrique Miranda Rota

Radioimmunotherapy (RIT) using Dual-Specific Antibodies for Cervical Cancer

2011 to 2017 | Grant
Debbie Fund (London, GB)
Source: Self-asserted source
Enrique Miranda Rota

Works (11)

Tuning the Hydrolytic Stability of Next Generation Maleimide Cross-Linkers Enables Access to Albumin-Antibody Fragment Conjugates and tri-scFvs

Bioconjugate Chemistry
2018 | Journal article
DOI: 10.1021/acs.bioconjchem.7b00795
EID:

2-s2.0-85042461799
Contributors: Forte, N.; Livanos, M.; Miranda, E.; Morais, M.; Yang, X.; Rajkumar, V.S.; Chester, K.A.; Chudasama, V.; Baker, J.R.
Source: Self-asserted source
Enrique Miranda Rota via Scopus - Elsevier

Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors

Immunity
2017 | Journal article
DOI: 10.1016/j.immuni.2017.03.013
EID:

2-s2.0-85017383025
Contributors: Arce Vargas, F.; Furness, A.J.S.; Solomon, I.; Joshi, K.; Mekkaoui, L.; Lesko, M.H.; Miranda Rota, E.; Dahan, R.; Georgiou, A.; Sledzinska, A. et al.
Source: Self-asserted source
Enrique Miranda Rota via Scopus - Elsevier

IMAC capture of recombinant protein from unclarified mammalian cell feed streams

Biotechnology and Bioengineering
2016 | Journal article
DOI: 10.1002/bit.25705
EID:

2-s2.0-84948080404
Contributors: Kinna, A.; Tolner, B.; Rota, E.M.; Titchener-Hooker, N.; Nesbeth, D.; Chester, K.
Source: Self-asserted source
Enrique Miranda Rota via Scopus - Elsevier

A plug-and-play approach to antibody-based therapeutics via a chemoselective dual click strategy

Nature Communications
2015 | Journal article
DOI: 10.1038/ncomms7645
EID:

2-s2.0-84926284885
Contributors: Maruani, A.; Smith, M.E.B.; Miranda, E.; Chester, K.A.; Chudasama, V.; Caddick, S.
Source: Self-asserted source
Enrique Miranda Rota via Scopus - Elsevier

Development of the designed ankyrin repeat protein (DARPin) G3 for HER2 molecular imaging

European Journal of Nuclear Medicine and Molecular Imaging
2015 | Journal article
DOI: 10.1007/s00259-014-2940-2
EID:

2-s2.0-84925500414
Contributors: Goldstein, R.; Sosabowski, J.; Livanos, M.; Leyton, J.; Vigor, K.; Bhavsar, G.; Nagy-Davidescu, G.; Rashid, M.; Miranda, E.; Yeung, J. et al.
Source: Self-asserted source
Enrique Miranda Rota via Scopus - Elsevier

Homogeneous bispecifics by disulfide bridging

Bioconjugate Chemistry
2014 | Journal article
DOI: 10.1021/bc5002467
EID:

2-s2.0-84906335290
Contributors: Hull, E.A.; Livanos, M.; Miranda, E.; Smith, M.E.B.; Chester, K.A.; Baker, J.R.
Source: Self-asserted source
Enrique Miranda Rota via Scopus - Elsevier

Acid-cleavable thiomaleamic acid linker for homogeneous antibody-drug conjugation

Chemical Communications
2013 | Journal article
DOI: 10.1039/c3cc45220d
EID:

2-s2.0-84882673481
Contributors: Castañeda, L.; Maruani, A.; Schumacher, F.F.; Miranda, E.; Chudasama, V.; Chester, K.A.; Baker, J.R.; Smith, M.E.B.; Caddick, S.
Source: Self-asserted source
Enrique Miranda Rota via Scopus - Elsevier

Generation and Characterization of a Diabody Targeting the α<inf>v</inf>β<inf>6</inf> Integrin

PLoS ONE
2013 | Journal article
DOI: 10.1371/journal.pone.0073260
EID:

2-s2.0-84883332077
Contributors: Kogelberg, H.; Miranda, E.; Burnet, J.; Ellison, D.; Tolner, B.; Foster, J.; Picón, C.; Thomas, G.J.; Meyer, T.; Marshall, J.F. et al.
Source: Self-asserted source
Enrique Miranda Rota via Scopus - Elsevier

Adenovirus-Mediated Sensitization to the Cytotoxic Drugs Docetaxel and Mitoxantrone Is Dependent on Regulatory Domains in the E1ACR1 Gene-Region

PLoS ONE
2012 | Journal article
DOI: 10.1371/journal.pone.0046617
EID:

2-s2.0-84867049698
Contributors: Miranda, E.; Maya Pineda, H.; Öberg, D.; Cherubini, G.; Garate, Z.; Lemoine, N.R.; Halldén, G.
Source: Self-asserted source
Enrique Miranda Rota via Scopus - Elsevier

Efficacy of oncolytic mutants targeting pRb and p53 pathways is synergistically enhanced when combined with cytotoxic drugs in prostate cancer cells and tumor xenografts

Human Gene Therapy
2010 | Journal article
DOI: 10.1089/hum.2010.019
EID:

2-s2.0-77958108351
Contributors: Radhakrishnan, S.; Miranda, E.; Ekblad, M.; Holford, A.; Pizarro, M.T.; Lemoine, N.R.; Halldén, G.
Source: Self-asserted source
Enrique Miranda Rota via Scopus - Elsevier

Oncolytic adenoviral mutants with E1B19KGene deletions enhance gemcitabine-induced apoptosis in pancreatic carcinoma cells and anti-tumor efficacy in vivo

Clinical Cancer Research
2009 | Journal article
DOI: 10.1158/1078-0432.CCR-08-2008
EID:

2-s2.0-63449117086
Contributors: Leitner, S.; Sweeney, K.; Öberg, D.; Davies, D.; Miranda, E.; Lemoine, N.R.; Halldén, G.
Source: Self-asserted source
Enrique Miranda Rota via Scopus - Elsevier
How many people are using ORCID?